Haleon reports slower organic revenue growth as delayed flu season hits sales
Haleon reported slower fourth-quarter growth of 2.1 percent as a delayed flu season hit sales. Weak US spending and competition also weighed on the results.
Insights:
Haleon plc announced on February 25, 2026, that its fourth-quarter organic revenue growth slowed to 2.1% from 3.4% in the prior quarter, attributing the decline to a delayed flu season that reduced sales of its respiratory-health products. The company, which operates in the consumer healthcare sector, noted that the weaker seasonal performance in the United Kingdom 
GB and the United States 
US directly reduced its reported growth for the period.
GB and the United States US directly reduced its reported growth for the period.Alongside its quarterly results, the company issued organic revenue guidance for 2026 of 3-5%. This projection is below the company-compiled poll market expectation of 4.4%. The development is significant as the guidance departs from investor expectations and follows a quarter where seasonal factors materially impacted the company's financial results.
